SpyGlass Pharma, Inc. SGP
Set alert
33.64 USD +1.40 +4.34%
At close · Nov 2
33.64 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
31.60 Day range 33.96
17.06 52-week range 33.96
- YTD
- +27.42%
- 1 year
- +27.42%
- Open
- 32.71
- Prev close
- 32.24
- Mkt cap
- 1.13B
- Vol
- 94.82K
- Avg vol
- 102.20K
- EPS
- -2.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.60
- High
- 33.96
- Forward P/E
- -11.95
- Beta
- 0.00
- Short ratio
- 9.43
- Inst. own
- 94.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 27.23
- 200-d avg
- 24.36
- 1y target
- 44.00
15m chart
Built from the cached five-day intraday bars.
Signals (37)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
Newest 20 of 37.
Key statistics
- Market cap
- 1.13B
- Enterprise value
- 845.81M
- Trailing P/E
- 0.00
- Forward P/E
- -11.95
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.84
- EPS (TTM)
- -2.51
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 234.19M
- Total debt
- 1.63M
- Return on equity
- 0.00%
- Shares outstanding
- 33.45M
- Short % of float
- 11.03%
- 50-day average
- 27.23
- 200-day average
- 24.36
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 44.00 +30.8% upside
Now 33.64
- Target (low)
- 37.00
- Target (mean)
- 44.00
- Target (high)
- 62.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.62247.
Financials — quick view
SGP Revenue — quarterly 0
SGP Net income — quarterly -19.86M
SGP EPS — quarterly -0.59
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.66 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.51442 | -0.59 | -0.08 | -14.69% |
| May 15, 2026 | Mar 31, 2026 | -0.67 | -0.69 | -0.02 | -2.99% |
| Mar 26, 2026 | Dec 31, 2025 | -0.57422 | -5.72 | -5.15 | -896.13% |
| Dec 3, 2025 | Sep 30, 2025 | — | -0.44776 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Raymond James | init | — | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | init | — | Buy |
| Mar 3, 2026 | Citigroup | init | — | Buy |
| Mar 3, 2026 | Leerink Partners | init | — | Outperform |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyglasspharma.com
News
- HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
- SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops
- SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
- EdgeConneX Enters Australia in Partnership with Stockland, with Hyperscale Data Center Campuses Planned in Sydney and Melbourne
- HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
- SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED)
Your note
Sign in to keep a note on SGP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| BEHBAHANI ALI | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.99% | 8,021,117 | 269.83M | Jun 29, 2026 |
| NEA Management Company, LLC | 22.11% | 7,392,301 | 248.68M | Jun 29, 2026 |
| Sands Capital Alternatives, LLC | 7.48% | 2,500,012 | 84.10M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 6.31% | 2,109,953 | 70.98M | Jun 29, 2026 |
| Blackrock Inc. | 2.13% | 711,712 | 23.94M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.02% | 674,143 | 22.68M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.95% | 317,053 | 10.67M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.87% | 291,272 | 9.80M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.74% | 247,196 | 8.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.73% | 245,044 | 8.24M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 229,706 | 7.73M | Jun 29, 2026 |
| abrdn Healthcare Investors | 0.64% | 214,473 | 7.21M | Jun 29, 2026 |